Home › Blastic Plasmacytoid Dendritic Cell Cancer
Blastic Plasmacytoid Dendritic Cell Cancer clinical trials recruiting in the U.S.
8 studies for Blastic Plasmacytoid Dendritic Cell Cancer are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04216524Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RecruitingPhase 2
6 Months – 65 Years · All sexes · Updated Jul 22, 2026 · NCT06013423SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT03113643Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
RecruitingObservational study
All ages · All sexes · Updated Jun 5, 2026 · NCT05430971CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04318678HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RecruitingPhase 1
Up to age 80 · All sexes · Updated May 18, 2026 · NCT03326921Q702 for the Treatment of Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 10, 2025 · NCT06712810Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.